FDA Raps Guangdong Firm Over Quality, Testing

Drug Industry Daily
A A
The FDA issued a warning letter to Chinese drugmaker Guangdong Zhanjiang Jimin Pharmaceutical following a May inspection of its Guangdong Province facility.

To View This Article:

Login

Subscribe To Drug Industry Daily